HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Acrivon Therapeutics (NASDAQ: ACRV) and maintained a $20 price target.

March 28, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Acrivon Therapeutics with a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards ACRV. This endorsement serves as a strong signal of confidence in the company's future prospects, potentially leading to increased investor interest and upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100